Collectively, these findings underscore the cGAS-STING signaling pathway as a critical regulator of immune-inflammatory responses in DCM, emphasizing its potential as a therapeutic target for alleviating complications associated with diabetes. This evidence concerns the gene CGAS and diabetes mellitus.